Search

Kura Oncology Inc

Ouvert

SecteurSoins de santé

10.53 0.38

Résumé

Variation du prix de l'action

24h

Actuel

Min

10.15

Max

10.67

Chiffres clés

By Trading Economics

Revenu

5M

-68M

Ventes

2.6M

21M

BPA

-0.77

Marge bénéficiaire

-327.331

Employés

260

EBITDA

7M

-66M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+154.9% upside

Dividendes

By Acuity

Prochains Résultats

3 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

70M

945M

Ouverture précédente

10.15

Clôture précédente

10.53

Sentiment de l'Actualité

By Acuity

27%

73%

55 / 340 Classement par Healthcare

Kura Oncology Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 oct. 2026, 20:07 UTC

Correlated Moves
Event

Kura Oncology to hold an investor webcast on October 13 to discuss Caspian Therapeutics and KO-7246 data from the EASD Annual Meeting.

7 oct. 2026, 19:45 UTC

Event
News

Kura Oncology Inc. will co-host a webcast with Caspian Therapeutics on October 13, 2026, to discuss KO-7246's preclinical data for diabetes treatment.

5 oct. 2026, 20:06 UTC

Social Media

Shares of Kura Oncology Inc fell, despite UBS reiterating a Buy rating with a $15 price target, citing strong early execution metrics for the Komzifti launch.

1 oct. 2026, 20:07 UTC

Social Media
Correlated Moves

Kura Oncology Inc shares fell modestly amid broader declines in the biotechnology sector, influenced by selloffs in key holdings like Nektar Therapeutics.

29 sept. 2026, 20:07 UTC

News
Event

Kura Oncology shares advanced after presenting preclinical data on KO-7246, a menin inhibitor showing promise for diabetes treatment at the European Diabetes Meeting.

24 sept. 2026, 20:07 UTC

Kura Oncology Inc's shares fell sharply, pulling back from Wednesday's close and settling near the bottom of its one-month trading range.

23 sept. 2026, 20:02 UTC

Correlated Moves

Kura Oncology Inc shares fell sharply, continuing a downward trend amid broader sector challenges and significant losses in the Direxion Daily S&P Biotech Bull 3X ETF.

22 sept. 2026, 23:01 UTC

Kura Oncology Inc saw a modest rise in after-market trading, peaking shortly after the regular session ended, despite remaining below its 20-day moving average.

21 sept. 2026, 19:25 UTC

Kura Oncology Inc shares fell sharply, currently trading below its 20-day moving average and near the lower end of its one-month range.

18 sept. 2026, 20:06 UTC

Kura Oncology Inc is seeing a slight increase in trading, moving higher since Thursday's close but remaining near the lower end of its one-month range.

17 sept. 2026, 20:08 UTC

Social Media

Kura Oncology Inc shares are advancing today, supported by increased retail commentary, despite pulling back from a session high earlier in the session.

16 sept. 2026, 20:10 UTC

Kura Oncology Inc shares fell sharply after an early spike, closing significantly below its 20-day moving average and near the lower end of its one-month range.

15 sept. 2026, 22:02 UTC

Kura Oncology Inc shares are higher in after-market trading, recovering from a low to a notable high during the session. No specific news was identified.

14 sept. 2026, 20:13 UTC

Kura Oncology Inc shares are higher in after-market hours, though no specific news was identified. The price remains below its 20-day moving average.

10 sept. 2026, 20:03 UTC

Social Media

Kura Oncology Inc shares are lower, continuing a three-day decline despite increasing sales and the approval of its menin inhibitor, KOMZIFTI.

9 sept. 2026, 22:41 UTC

Kura Oncology Inc shares are rising in after-market trading, reflecting positive momentum in the biotechnology sector despite earlier session declines.

8 sept. 2026, 20:02 UTC

News
Social Media

Kura Oncology Inc shares are lower today, influenced by declines in the Biotechnology sector despite the appointment of a new Chief Financial Officer.

3 sept. 2026, 19:47 UTC

Kura Oncology Inc shares are lower today, with no specific news driving the decline. Earlier, the stock rebounded from a session high.

2 sept. 2026, 22:01 UTC

Kura Oncology Inc shares are higher in after-market trading, reflecting strength amid weaker-than-expected job growth reported by ADP.

28 août 2026, 20:08 UTC

Kura Oncology Inc shares are lower today, reflecting broader market trends and rising U.S. Treasury yields amid concerns over inflation and monetary policy.

27 août 2026, 23:46 UTC

Kura Oncology Inc shares are higher in after-market hours, rebounding from earlier declines and staying above recent moving averages. No specific news was identified.

26 août 2026, 23:41 UTC

Kura Oncology Inc shares are higher in after-market trading, supported by positive market sentiment despite no specific company news.

25 août 2026, 23:06 UTC

News

Kura Oncology Inc. reached a new 52-week high after CEO Troy Wilson acquired 100,000 shares for approximately $1.24 million, reflecting strong market sentiment.

24 août 2026, 23:31 UTC

News
Social Media

Kura Oncology shares are higher in after-market hours following CEO Troy Wilson's $1.2 million stock purchase, boosting his ownership to 1.214 million shares.

21 août 2026, 22:56 UTC

Kura Oncology shares declined in after-market trading, continuing a downward trend since Friday's close, despite remaining above the 20-day moving average.

20 août 2026, 23:16 UTC

Kura Oncology Inc shares are higher in after-market trading, despite no specific news to explain the move. The stock remains above its 20-day moving average.

19 août 2026, 19:21 UTC

Social Media

Kura Oncology Inc shares are higher, supported by positive biotechnology sentiment and social media discussions about a recent swing position at $12.57.

18 août 2026, 23:06 UTC

Kura Oncology shares are higher in after-market trading, aligning with broader market trends amid rising sovereign bond yields and inflation concerns.

17 août 2026, 22:51 UTC

Social Media
News

Kura Oncology shares rose in after-market trading after CEO Troy Wilson's $1.11 million stock purchase and positive earnings report highlighting $9.1 million in revenue.

14 août 2026, 22:01 UTC

Kura Oncology Inc shares are higher in after-market trading, recovering from an earlier decline. The stock remains above its 20-day moving average.

Comparaison

Variation de prix

Kura Oncology Inc prévision

Objectif de Prix

By TipRanks

154.9% hausse

Prévisions sur 12 Mois

Moyen 26.815 USD  154.9%

Haut 40 USD

Bas 12.15 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

11 ratings

11

Achat

0

Maintien

0

Vente

Sentiment

By Acuity

55 / 340Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.